Table 2.

Impact of achievement of clinical and endoscopic targets on subsequent disease course

Endoscopic target	Frequency observed, n (%)	Risk of treatment failure* if target not achieved (logrank HR, 95% CI)	P value	Risk of corticosteroids, admission or surgery if target not achieved (logrank HR, 95% CI)	P value	Risk of surgery if target not achieved (logrank HR, 95% CI)	P value
SES-CD $\le$ 2	25 (50)	11.62 (3.33 to 40.56)	0.003	5.74 (1.16 to 28.56)	0.07	3.44 (0.48 to 24.53)	0.25
Absence of ulcers	28 (56)	6.45 (1.80 to 23.09)	0.007	2.80 (0.55 to 14.18)	0.23	4.21 (0.58 to 30.73)	0.18
>50% reduction in SES-CD	35 (70)	30.30 (6.93 to 132.40)	<0.0001	13.74 (2.25 to 83.84)	0.002	8.28 (0.90 to 76.02)	0.03†
SES-CD $\le 3$	32 (64)	24.13 (5.99 to 97.20)	<0.0001	11.21 (1.98 to 63.40)	0.005	6.68 (0.81 to 55.64)	0.06
Combined remission (SES-CD $\le$ 2 and HBI <5)	19 (38)	6.78 (1.94 to 23.70)	0.04	2.69 (0.53 to 13.74)	0.23	2.26 (0.38 to 13.57)	0.37
Combined remission (SES-CD $\le$ 3 and HBI <5)	24 (48)	11.07 (3.18 to 38.49)	0.004	5.43 (1.10 to 26.95)	0.08	3.15 (0.44 to 22.35)	0.29

Bold values signify statistical significance (p value ${\displaystyle \le }$ 0.05).

*Treatment failure defined as the need for: (1) change of biological therapy for active disease (2) corticosteroid use (3) CD-related hospitalisation or (4) surgery.

†Non-significant due to 95% CI.

HBI, Harvey Bradshaw Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease.